Document:

Exhibit 4.2(r)

 

“CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS
DOCUMENT HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION.  CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.”

 

AGREEMENT dated18 August 2004

 

BETWEEN

 

AUTOGEN RESEARCH PTY LIMITED(1) ABN 84 074 636 847
of Pigdons Road, Waurn Ponds Victoria 3217 (“Autogen
Research”)

 

AND

 

INTERNATIONAL DIABETES INSTITUTE ACN 007 342 412 of
260 Kooyong Road, Caulfield, Victoria 3162 (“IDI”)

 

RECITALS

 

A.                                   On
14 January 1998 Autogen Research (then named Autogen Pty Ltd) and IDI
entered into an agreement entitled Research, Licence and Commercialisation
Agreement (“Research  Agreement
for Human Diabetes / Obesity Discovery”) setting out the terms and conditions
for research to be carried out with the participation of the parties.

 

B.                                    The
parties now agree to extend the Research Agreement subject to the terms and
conditions of this Agreement.

 

AGREEMENT

 

1.             EXTENSION OF TERM

 

With effect on and from 1 July 2004 the parties
agree that the term of the Research Agreement is extended until 30 June 2005
(“Extended Term”) (unless the Research
Agreement is earlier terminated in accordance with its terms).  During the Extended Term the terms and
conditions of the Research Agreement will continue to apply except to the
extent to which they are inconsistent with anything set out in this Agreement,
in which case the provisions of this Agreement will prevail to the extent of
the inconsistency.

 

2.             PAYMENT AND RESEARCH PROPOSAL DURING EXTENDED TERM

 

During the Extended Term:

 

(a)                                  the
budget set out in Schedule 1 to this Agreement will be substituted for any
payment program previously applying under the Research Agreement; and

 

(b)                                 the
research plan (including any milestones set out therein) set out in Schedule 2
to this Agreement will be substituted for any research proposal and workplans
previously applying under the Research Agreement.

 

(1) Autogen Research Pty
Ltd is a wholly-owned subsidiary of ChemGenex Pharmaceuticals Limited (ABN 79
000 248 304).

 

1

 

	
  EXECUTED
  AS AN AGREEMENT

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SIGNED FOR AND BEHALF of

  	
   

  	
  )

  	
   

  	
   

  
	
  AUTOGEN RESEARCH PTY

  	
   

  	
  )

  	
   

  	
   

  
	
  LIMITED ABN 84 074 636 847

  	
   

  	
  )

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Director

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SIGNED FOR AND BEHALF of

  	
   

  	
  )

  	
   

  	
   

  
	
  INTERNATIONAL DIABETES

  	
   

  	
  )

  	
   

  	
   

  
	
  INSTITUTE ACN 007 342 412

  	
   

  	
  )

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Secretary

  	
   

  	
   

  	
   

  	
  Director

  

 

2

 

SCHEDULE 1

 

Payments July 1, 2004 – June 30, 2005 payable by Autogen to IDI
as follows:

 

Funding consists of quarterly payments of $[*], plus GST. The first
payment will be made in September 2004. Subsequent payments will be made
upon satisfactory completion of the performance reviews required under clause 5
of the Research Agreement, those performance reviews (for the avoidance of
doubt) to be completed by the following dates –

 

•                  12 October, 2004

 

•                  12 January, 2005

 

•                  12
April, 2005

 

IDI is required to forward the reviews to Autogen and following
satisfactory performance, IDI will then invoice Autogen for quarterly payment
of research in advance.

 

3

 

SCHEDULE 2.
– INTERNATIONAL DIABETES INSTITUTE GENETICS RESEARCH LABS

 

CHEMGENEX
PHARMACEUTICALS HUMAN GENOMICS PROGRAM RESEARCH PLAN

 

2004 / 2005

 

Human Genomics Gene
Discovery Program

 

This section outlines
our research plan to identify genes influencing quantitative physiological
measures of Type 2 diabetes, obesity and related metabolic disorders using
several populations. QTLs identified in Mexican American families from the San
Antonio Family Heart Study (SAFHS), Wisconsin families from the MRCOB study and
Mauritian families, genome wide scanned by AGT Biosciences, will be
investigated.

 

QTL Selection

 

Three or more QTLs from the SAFHS, MRCOB or Mauritius studies will be
analysed simultaneously to increase the number of potential disease genes under
investigation.  This approach should
provide choice in candidate gene selection and allow for certain QTLs to be
excluded in the event that high probability candidates are identified that have
already been covered by patents or that do not represent good drug
targets.  Selected QTLs have been fine
mapped to an average of 2 cM resolution to narrow the target region to the
minimum achievable interval. Current QTLs under investigation include:

 

	
  •

  	
   

  	
  [*]

  	
   

  	
  SAFHS

  	
   

  	
  [*] genes covered

  
	
  •

  	
   

  	
  [*]

  	
   

  	
  SAFHS

  	
   

  	
  [*] genes covered

  
	
  •

  	
   

  	
  [*]

  	
   

  	
  Mauritius

  	
   

  	
  [*] genes covered

  

 

Future QTLs may include:

 

	
  •

  	
   

  	
  [*]

  	
   

  	
  SAFHS

  

 

Positional Candidates and
Druggable Gene Ranking Strategy

 

The ranking strategy has been altered to include a stage of the SNPScan
where all putative druggable genes will be evaluated with equal priority as
positional candidates ranked on functional annotation.  This measure has been introduced in response
to a general concern that lack of speed in identifying disease genes in this
program will result in an increasingly limited intellectual property space for
protection of newly identified disease genes. Additionally, since chemically
tractable or druggable targets are of prime interest to AGT Biosciences for
development of therapies, it is critical that genes that fall directly into
this class and are located under a linkage peak are investigated first.

 

Five criteria shall be used in the ranking scheme relying on functional
annotations derived from published literature and ontological grouping based on
primary amino acid sequence analysis; membership of families known to be
chemically tractable by small molecule drugs, or amenable to antibody or protein
type therapeutics; association of SNP markers across the region to the
phenotype; gene expression level differences in mammalian tissues discordant
for the phenotype; and location of the candidate gene relative to the centre of
the linkage peak (human and baboon tissue). While these measures have been
devised based on the latest theory and methods available in the field, due to
the complex nature of the disease’s underlying genetic architecture and
mechanism of pathogenesis, this strategy cannot

 

4

 

guarantee that the actual disease gene will be among the top ranked
candidates.

 

Ranking Criteria Summary

 

1.               Functional
positional candidates as determined by online database information mining

2.               Chemical tractability
as determined by membership of families targeted by therapeutics

3.               SNPScan for
association of variants to disease – gene centric SNP selection

4.               Gene expression
levels by microarray in tissue

5.               Location relative
to centre of linkage peak

 

SNPScan

 

The SNPScan shall proceed in stages, the first stage shall focus on the
top ranked candidate genes based on their known or inferred function and
differential expression profiles in diseased vs. normal tissues (if available).
The second stage shall include those genes likely to be druggable.  Depending upon the number of genes and
qualifying SNPs, these stages may be combined or spread over additional stages
to facilitate their genotyping in the laboratory.  The third through to nth stage of
the scan shall examine SNPs in all genes starting in the centre of the linkage
peak and progressively working outward. 
Each QTL shall be divided up into 5 or more stages depending upon the
size of the interval. At each iterative stage, the latest release of the online
SNP databases will be reviewed for newly submitted SNPs appearing in genes that
were analysed in earlier stages. Qualifying SNPs will be incorporated into the
next stage.

 

SNP Selection

 

The gene centric approach of SNP selection for each gene is as follows:
SNPs will be selected from public databases for each gene, and shall include
all exonic SNPs and SNPs in conserved flanking regions identified by comparison
to other mammalian genomes. In particular, SNPs will be included if they fall
within the putative promoter region (usually within 1-2 kb of the
transcriptional start site), and up to 1 kb extending into intron 1 based on
GGG trinucleotide and CpG dinucleotide content. SNPs falling within the 3’ UTR
and flanking region will also be included if conserved.  SNPs lying within conserved intronic and
intergenic regions will also be included as these may comprise alternate exons
(not yet annotated), enhancer regions, distant exons or complete genes not
predicted by current software algorithms. However, these latter SNPs in the
current database are sufficiently numerous to require sub-sampling. Therefore,
we propose to initially select 1-2/SNPs per conserved region (size up to 10kb),
and limit these selections to those SNPs with evidence of being polymorphic (i.e.
“-cluster” or “–2-hit” on database). In the event the QTL is fully scanned
without detecting a disease related gene, we may initiate the typing of
additional intergenic and intronic SNPs.

 

Where a SNP is found associated or trending toward association (p<0.1),
we shall type this within the entire cohort. If the association remains or
strengthens, we shall proceed with typing additional SNPs within the gene
(intronic) and those that may have appeared on the database since the initial
selection.

 

5

 

Genotyping
Cohort

 

The selected SNPs shall be typed in the founders of the family
collection in which the QTL was identified to determine wether the SNP is
polymorphic in the cohort, and whether it is associated with a disease related
trait.  At the conclusion of typing for
each stage and prior to commencement of genotyping on the next stage, the data
shall be analysed by the AGT Biosciences Centre for Statistical Genomics.  If a positive association is identified between
a SNP and a trait, the association shall be verified by typing the SNP in the
whole family cohort and the association signal again measured.  An increase in the significance of the
association suggests that the genetic variation is influencing the trait or is
in LD with a variant that is influencing the trait.  If this is observed a conditional linkage
analysis on these variants will be performed to determine its contribution to
the QTL signal.

 

If no significant trait association among any of the SNPs typed within
a SNPScan stage is observed, the next progressive stage of the SNPScan can
commence.  Since, as mentioned above, the
GenBank and dbSNP databases are constantly being updated, the region will
likely require re-annotation.  If this is
the case, a review of all previously SNPscanned regions shall be carried out so
as to include genes and SNPs that appear on the new database release.  Additionally a review of the tools and
available mammalian genomic sequence shall be made to improve our detection of
evolutionarily conserved regions.

 

Exhaustive genetic
variation analysis of ranked candidate genes

 

Once ranked the candidate disease gene(s) will be evaluated by
exhaustive variant analysis by resequencing of up to 50 individuals from the
selected family cohort to identify all genetic variants segregating in the
population.  To maximise the chances of
identifying functional variants within the candidate gene, we shall resequence
all exons together with conserved regions from intronic, 5’ and 3’ flanking
regions as determined by alignment with other mammalian species (eg
mouse).  Those variants shall then be
genotyped in the entire cohort and tested for whether they contribute to the
original linkage signal and thus influence the variation in the quantitative
trait.

 

Bioinformatics

 

The GeneSniffer script will continue to be used to rank functional and
druggable positional candidate genes. 
Further development for the script includes:

 

•                  Inclusion of
rank parameter based on proximity to peak of linkage signal

•                  Development of a
statistical assessment of the significance of the genes total “hit score” by
evaluating scores obtained under the null hypothesis.

 

Summary

 

1                                QTL
Selection.

 

2                                Fine
Mapping of QTL.

 

3                                Positional
candidate gene selection.

 

4                                SNPScan
of public SNPs using association, conditional linkage and localised linkage
disequilibrium.

 

6

 

5                                Microarray
based gene expression levels of genes in disease vs. normal tissue (Human,
Baboon, ISR).

 

6                                Location
of gene relative to linkage peak.

 

7                                Determine
patent position on top ranked candidates.

 

8                                Hypothesis
development

 

9                                Proceed
with full variant analysis of top ranked genes based on SNPScan and expression
data combined with commercial objectives.

 

10                          Identify
all genetic variation in gene by resequencing.

 

11                          Type
genetic variants in extended family pedigrees.

 

12                          Test
whether genetic variation accounts for linkage signal – identification of
disease related gene. Continue through steps 7-12 on progressively lower ranked
genes until disease influencing gene identified.

 

7

 

Israeli Sand Rat
Candidate Genes

 

We shall continue
to evaluate genes discovered by differential expression in the Israeli sand rat
polygenic animal model of type 2 diabetes and obesity.  Dependent upon functional information
available for these genes (literature based and AGT generated), genetic
variants will be genotyped in selected cohorts where QTLs are found for
relevant phenotypes.  Variation within
the gene will then be assessed for association with relevant available
quantitative traits by the AGT Biosciences Centre for Statistical Genomics.

 

SNPs will be selected as above according to our gene centric approach
and genotyped first in the founders of the cohort to determine whether
polymorphic. If they are polymorphic within the cohort, they shall be typed in
the entire cohort and statistical association analysed. Genes currently
undergoing statistical analysis include:

 

	
  •

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  MRCOB & SAFHS

  
	
  •

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  MRCOB

  
	
  •

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  Mauritius

  
	
  •

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  MRCOB

  

 

Genes that may be analysed in the future

 

	
  •

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  To be determined

  

 

SELS was found to be strongly associated with several circulating
markers of inflammation in the MRCOB cohort. 
We shall further investigate this association in the SAFHS cohort in
addition to phenotyping of other relevant markers in this cohort.

 

Metabolic Syndrome QTL
3q27 – (NIH and NHMRC funding)

 

Funding was obtained during the 2003/2004 financial
year to investigate the positional candidate genes [*] and [*] under the [*] linkage peak identified by Ahmed Kissebah in
the MRCOB cohort.  These genes will be
re-sequenced in 50 individuals selected from families in this cohort
contributing most strongly to the linkage signal.  Identified variants will then be genotyped in
the whole cohort and association and conditional linkage analysis undertaken to
determine the level of contribution of the gene to the linkage signal.  Additionally, gene expression level differences
will be analysed using a BAC chip and cDNA obtained from muscle biopsies of
selected MRCOB study participants.

 

A recent re-run of the GeneSniffer script revealed
another strong functional positional candidate (majority homolog score) in the [*] region [*] (guanine nucleotide binding protein (G
protein), beta polypeptide 4). This gene will be considered for re-sequencing
and genotype analysis.

 

8

 

	
  Milestones

  	
   

  	
  Completion Date

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  SNPScan
  [*]

  	
   

  	
   

  	
   

  
	
  Complete typing SNPs in all genes

  	
   

  	
  March 2005

  	
   

  
	
  Commence re-sequencing on selected genes

  	
   

  	
  June 2005

  	
   

  
	
  SNPScan
  [*]

  	
   

  	
   

  	
   

  
	
  Complete typing SNPs in potentially druggable genes

  	
   

  	
  December 2004

  	
   

  
	
  Complete 1-2 additional SNPScan stages

  	
   

  	
  June 2005

  	
   

  
	
  SNPScan
  [*]

  	
   

  	
   

  	
   

  
	
  Complete typing SNPs in potentially druggable genes

  	
   

  	
  March 2005

  	
   

  
	
  Complete one additional SNPScan stage

  	
   

  	
  June 2005

  	
   

  
	
  Israeli
  Sand Rat Candidate Genes

  	
   

  	
   

  	
   

  
	
  [*] complete re-sequencing

  	
   

  	
  October 2004

  	
   

  
	
  [*] complete genotyping and
  phenotyping

  	
   

  	
  October 2004

  	
   

  
	
  [*] complete statistical
  analysis

  	
   

  	
  November 2004

  	
   

  
	
  [*] complete statistical analysis

  	
   

  	
  June 2005

  	
   

  
	
  Metabolic
  Syndrome [*]

  	
   

  	
   

  	
   

  
	
  [*] complete re-sequencing

  	
   

  	
  December 2004

  	
   

  

 

9Exhibit 4.2(s)

 

“CONFIDENTIAL TREATMENT
REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED AND HAVE
BEEN SEPARATELY FILED WITH THE COMMISSION. 
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.”

 

SPONSORED
CLINICAL STUDY AGREEMENT

 

This Clinical Study
Agreement (the “Agreement”) is made this 14th day of April, 2003 (“Effective
Date”), between The University of Texas M.D. Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, Texas 77030 (“Institution”), a component of The
University of Texas System (“System”), and ChemGenex Therapeutics, Inc.,
3475 Edison Way, Suite M, Menlo Park, California 94025 (“Sponsor”).  Institution and Sponsor agree as follows:

 

1. PROTOCOL

 

1.1                                 Institution
agrees to use its best efforts to conduct a clinical study of Sponsor’s study
drug, as an independent contractor, in accordance with Institutional policy,
applicable laws and regulations and the protocol entitled “A Phase II
Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635)
in the Treatment of Myelodysplastic Syndrome (MDS)” (the “Protocol”), as
described in Exhibit A attached hereto and incorporated herein (the “Study”).
The Study shall be supervised by Jorge Cortes-Franco, M.D. (“Principal
Investigator”), at Institution, with assistance from associates and colleagues
(collectively, “Other Investigators”), as required.

 

1.2                                 The
Institution shall require the Principal Investigator and the Other
Investigators engaged in the Study each individually to complete and return to
Sponsor the Disclosure of Financial Interests and Arrangements attached hereto
as Exhibit C (“Disclosure”). Sponsor shall hold such Disclosures in
confidence and shall only use such Disclosures as necessary to comply with FDA
regulatory requirements set forth in 21 CFR § 54. By completing the
Disclosure, the Principal Investigator and the Other Investigators shall
represent that the Disclosure supplied is truthful and accurate. Failure of
Investigators to complete and return the Disclosure(s) to Sponsor shall be
considered a material breach of this Agreement. In the event that circumstances
change during the Study and the Disclosure submitted by the Principal
Investigator and the Other Investigators engaged in the Study is no longer truthful
and accurate, the Principal Investigator and/or the Other Investigators shall
promptly submit to Sponsor updated Disclosure(s) reflecting the new
circumstances.

 

1.3                                 Sponsor
agrees to engage the services of Institution to conduct the Study and further agrees
to provide at no cost to Institution the study drug and related materials as
referenced in the Protocol (the “Study Drug “) for the conduct of the Study.
The Study shall be conducted at Institution.

 

1.4                                 Neither
the Principal Investigator nor the Study location may be changed without
Sponsor’s prior written consent.

 

1.5                                 Institution
and Sponsor shall comply with all applicable laws, rules and regulations
in performance of the Studies. Independent assurance that the Study is designed
in a manner appropriate to ensure that the subjects are protected shall be
provided by the Institution’s Ethics Committee or Institutional Review Board
(collectively, “IRB”). The Institution shall formulate, in cooperation with the
Sponsor, informed consent agreements. Institution shall ensure that written
informed consent agreements, as well as other applicable consents required by
law, are obtained from each individual Study subject before such individual is
allowed to participate as a subject in the Studies. Breach of this Section 1.5
shall constitute a material breach of this Agreement. Sponsor shall be entitled
to review and revise as appropriate such informed consent form or any
modification thereof prior to use by the Institution, subject to subsequent
approval by the IRB.

 

1

 

1.6                                 In
accordance with applicable laws and regulations, Institution shall cause
Principal Investigator to promptly, but in no event more than twenty-four (24)
hours later, advise Sponsor of any serious adverse reactions or side-effects
relating to the Study Drug or arising during the course of performance of the
Study. Such notification by Principal Investigator shall be by telephone and as
directed in the Protocol. Sponsor and Institution shall jointly and promptly
deal with all such serious adverse reactions or side effects and take
appropriate measures necessary to safeguard the subjects.

 

1.7                                 Institution
shall not use independent contractors to perform any services to be performed
by Institution under the Study without the prior written consent of Sponsor.

 

2. AWARD

 

2.1                                 In
consideration for performance of the Study by Institution, Sponsor shall pay
Institution a maximum of [*] dollars ($[*]) per patient for Study expenses for
up to fifteen (15) patients, according to the study budget and payment schedule detailed
in Exhibit B. This amount, shown by approximate category of expense in Exhibit B
is attached hereto for information only. The first installment is payable
within thirty (30) days of the Effective Date, and subsequent installments are
payable quarterly. In no event shall Sponsor be obligated to pay to Institution
any aggregate amount in excess of [*] dollars ($[*]) unless Sponsor consents to
do so in writing.  Breach of Section 2.1
shall constitute a material breach of this Agreement.

 

3. TERM

 

3.1                                 This
Agreement shall continue in force until the earlier of completion of the Study
as mutually agreed upon by the parties or twenty-four (24) months from the
Effective Date; provided, however, that Sponsor may terminate the Agreement at
will by giving thirty (30) days advance written notice to Institution.  Institution may terminate this Agreement for
material breach by Sponsor, if such breach remains uncured thirty (30) days
after Sponsor receives written notice of such breach from Institution.

 

3.2                                 Upon
early termination of this Agreement other than for Institution’s material
breach and subject to the maximum amount specified in Article 2, Sponsor
shall be liable for all reasonable and documented costs incurred by Institution
in performance of the Study at the time of such termination, and all
non-cancelable obligations reasonably relating to such performance. Sponsor
shall pay Institution for such costs within thirty (30) days of receipt of an invoice
for same.

 

3.3                                 Upon
termination of this Agreement, Institution shall return Sponsor’s Study Drug,
Confidential Information of the Sponsor and other Study materials.

 

4. INDEMNIFICATION

 

4.1                                 Institution
shall, to the extent authorized under the Constitution and laws of the State of
Texas, indemnify and hold Sponsor, its officers, agents, employees, independent
contractors and affiliates (“Sponsor Indemnitees”) harmless from any and all
liability, loss, costs (including reasonable attorneys’ fees) or damages
resulting from the negligent acts or omissions or willful malfeasance of
Institution, its agents, employees or related personnel (including, but not
limited to postgraduate students and other students) arising out of the
activities to be carried out pursuant to the obligations of this Agreement;
provided, however, that Institution shall not hold such Sponsor Indemnitees
harmless from claims arising out of the negligence or willful malfeasance of
such Sponsor Indemnitees.

 

2

 

4.2                                 Sponsor
shall indemnify and hold harmless System, Institution, their Regents and
officers, agents, employees or related personnel (including, but not limited to
postgraduate students and other students) of Institution or System (“Institution
Indemnities”) from any liability, loss, costs (including reasonable attorneys’
fees) or damages resulting from judgments or claims against them arising out of
the activities to be carried out pursuant to the obligations of this Agreement,
including but not limited to the use by Sponsor of the results of the Study;
provided however, that Sponsor’s obligation to indemnify and hold harmless
shall not apply to the extent such liability, loss, costs or damages result
from:

 

a.                                       the
negligent failure of Institution or such Institution Indemnitee to adhere to
the terms of the Protocol, or the material failure of Institution or such
Institution Indemnitee to comply with any applicable governmental requirements
or to perform its obligations under the Agreement; or

 

b.                                      the
negligence or willful malfeasance by a Regent, officer, agent, employee or
related personnel (including, but not limited to postgraduate students and
other students) of Institution or System.

 

4.3                                 As
a condition of indemnification by a party, such party seeking indemnification
shall provide the indemnifying party with prompt written notice of any such
claim or action arising out of the activities to be carried out pursuant to the
obligations of this Agreement. Such indemnifying party shall have the right,
but not the obligation, to control the defense of any and all such claims and
actions and shall have the right to select and engage counsel of its choice.
The indemnified party shall cooperate fully with the indemnifying party in
defense of any and all claims and actions. Institution shall not settle a claim
while including an admission of wrongdoing or negligence on the part of Sponsor
without Sponsor’s written approval. Sponsor shall not settle a claim while
including an admission of wrongdoing or negligence on the part of Institution
without Institution’s written approval. This Section 4.3 is subject to the
statutory duties of the Texas Attorney General.

 

4.4                                 Each
party shall maintain commercially reasonable levels of insurance or other adequate
forms of protection to satisfy its indemnification obligations under this
Agreement as follows:

 

a.                                       University,
as a component of System, is an agency of the State of Texas and is
self-insured pursuant to The University of Texas System Professional Medical
Malpractice Self-Insurance Plan, under the authority of Chapter 59, Texas
Education Code. University has and will maintain in force during the term of
this Agreement adequate insurance to cover its indemnification obligations
hereunder.

 

b.                                      Sponsor
agrees to maintain reasonable coverage for such liabilities either through
commercial insurance or a reasonable self-insurance mechanism, and information
concerning commercial insurance of a reasonable self-insurance mechanism will
be reasonably provided to the University.

 

5.
REPRESENTATIONS

 

5.1                                 Institution
represents that it is qualified and permitted to enter into this Agreement and
that the terms of this Agreement are not inconsistent with its other
contractual arrangements. Institution represents that it is not constrained by
any existing agreement in providing complete disclosures to Sponsor concerning
obligations to be performed under this Agreement.

 

3

 

5.2                                 Institution
represents that this Agreement is a legal and valid obligation binding upon
Institution and enforceable in accordance with its terms.

 

5.3                                 During
the term of this Agreement, Institution covenants that it shall not enter into
any agreement to provide services which would in any way materially impair its
ability to complete the Study in a timely fashion.

 

5.4                                 Institution
represents that it has never been and, to the best of its knowledge after
reasonable inquiry, its employees have never been 1) debarred or 2) convicted
of a crime for which a person can be debarred, under section 306(a) or
306(b) of the Generic Drug Enforcement Act of 1992 (“Section 306(a) or
(b)”). Institution represents that it has never been and, to the best of its
knowledge after reasonable inquiry, none of its employees has ever been 1)
threatened to be debarred or 2) indicted for a crime or otherwise engaged in
conduct for which a person can be debarred, under Section 306(a) or
(b). Institution covenants that it will promptly notify Sponsor in the event of
any such debarment, conviction, threat, or indictment. The terms of the
preceding sentence shall survive the termination or expiration of this
Agreement for a period of three (3) years.

 

5.4                                 Institution
shall also provide all information to Sponsor necessary to comply with any
disclosure requirements, including any information required to be disclosed in
connection with any financial relationship between Sponsor and the Principal
Investigator as required per Exhibit C.

 

6. PUBLICATION
AND CONFIDENTIALITY

 

6.1                                 Institution
reserves the right to publish the results of the Study, with due regard to the
protection of Sponsor’s confidential information. Institution will submit the
manuscript of any proposed publication to Sponsor at least thirty (30) days
before publication, and Sponsor shall have the right to review and comment upon
the publication in order to protect Sponsor’s Confidential Information.
Institution shall delete from such publication or release any of Sponsor’s
Confidential Information. Upon Sponsor’s request, publication will be delayed
up to sixty (60) additional days to enable Sponsor to secure adequate
intellectual property protection of property of Sponsor that would be affected
by said publication.

 

6.2                                 Except
as otherwise required by law or regulation, neither party shall release or
distribute any materials or information containing the name of the other party
or any of its employees without prior written approval by an authorized
representative of the non-releasing party, but such approval shall not be unreasonably
withheld.

 

6.3                                 The
parties may wish, from time to time, in connection with work contemplated under
this Agreement, to disclose confidential information to each other, including,
but not limited to, patent applications, technology or business plans and all
information relating thereto; all proprietary biological, chemical or other
materials; applications, formulas, manufacturing processes, basic scientific
data, prior and ongoing clinical trial data and formulation information; and
any other information designated in writing as “Confidential” by a party (“Confidential
Information”).  Each party agrees not to
use the other party’s Confidential Information except for purposes expressly
authorized in this Agreement, including Institution’s right to publish the
results of the Study as specified in Section 6.1 herein. Each party shall
not disclose any of the other party’s Confidential Information to third parties
for a period of five (5) years from receipt thereof, provided that the
recipient party’s obligation shall not apply to information that:

 

a.                                       is
already in the recipient party’s possession at the time of disclosure thereof;

 

4

 

b.                                      is
or later becomes part of the public domain through no fault of the recipient
party;

 

c.                                       is
received from a third party having no obligations of confidentiality with
respect thereto to the disclosing party;

 

d.                                      is
independently developed by the recipient party without any breach of this
Agreement; or

 

e.                                       is
required by valid law or regulation to be disclosed; provided that, in the
event that information is required to be disclosed pursuant to this subsection e.,
the party required to make disclosure shall notify the other party prior to
such disclosure, and shall use reasonable efforts to cooperate with such party
to allow assertion of whatever exclusions or exemptions may be available to it
under such law or regulation.

 

7. INTELLECTUAL
PROPERTY RIGHTS

 

7.1                                 “Invention”
shall mean any discovery, invention, technology, material, information,
concept, or idea, whether or not patentable, made either during or arising out
of the conduct of the Study, or using materials provided by Sponsor under this
Agreement, including but not limited to processes, methods, software, tangible
research products, formulas and techniques, improvements thereto, and know-how
related thereto.

 

7.2                                 Institution
shall require that the Principal Investigator to promptly disclose in writing
to its Intellectual Property Committee and to Sponsor any Inventions made by:
1) employees, independent contractors, affiliates and related personnel
(including, but not limited to postgraduate students and other students) of the
Institution and/or 2) the Principal Investigator and Other Investigators. All
Inventions and any information with respect thereto shall be subject to
confidentiality obligations commensurate with those set forth in Section 6.3
herein.

 

7.3                                 All
rights and title to any Invention conceived and reduced to practice as a direct
result of the performance of the work conducted under this Agreement and all
intellectual property rights related thereto provided by Sponsor to Institution
shall be owned solely by Sponsor. Institution shall not use the Study Drug
other than to perform its obligations under this Agreement (the “Permitted Use”).
For clarity, any Inventions arising from any use of the Study Drug by
Institution, the Principal Investigators or Other Investigators outside the
Permitted Use, and all intellectual property rights related thereto, shall be owned
solely by Sponsor.

 

7.4                                 Institution
hereby assigns to Sponsor all right, title and interest in and to such
Inventions (including intellectual property rights related thereto) of its
employees, agents and related personnel (including, but not limited to, the
principal investigator, Other Investigators, postgraduate students and other
students, as applicable) conceived and reduced to practice as a direct result
of the performance of the work conducted under this Agreement. Sponsor shall
pay any reasonable costs necessary to affect such assignment. Costs associated
with procuring, maintaining or enforcing intellectual property rights
associated with any Invention subsequent to its assignment shall be borne by
Sponsor.

 

8. REGULATORY

 

8.1                                 Each
party shall promptly notify the other party of any FDA regulatory inspections
of which it becomes aware relating to the Study. Sponsor shall have the right
to be present at any such 

 

5

 

inspections
and shall have the opportunity to provide, review, and comment on any responses
that may be required.

 

8.2                                 Sponsor’s
representatives may visit and/or meet with Institution, Principal Investigator,
Other Investigators, consultants or Sponsor-approved subcontractors at
reasonable times and with reasonable frequency during normal business hours to
observe the progress of the Study and review Study records. Institution shall
cause Principal Investigator to assist Sponsor in scheduling such visits.

 

8.3                                 Subject
to the requirements of Articles 6 and 7, Institution shall retain in its
possession copies of any and all data, documents or information related to the
performance of this Agreement solely as required for regulatory, legal or
insurance purposes.  Institution shall
maintain its records in a professional manner so as to permit Sponsor to review
the data, documents or information in full without disclosing to Sponsor any
third party confidential or proprietary information.  Institution shall maintain all such records
for a period of three (3) years or as required by applicable FDA
guidelines, whichever is longer. Upon expiration of such applicable FDA
guideline(s) or after three (3) years, whichever is longer, Sponsor shall,
upon Institution’s request and at Sponsor’s expense, direct that such records
be delivered to Sponsor.

 

9. GENERAL

 

9.1                                 This
Agreement, including the attached Exhibits A, B and C, constitutes the entire
and only Agreement between the parties relating to the Study, and all prior
negotiations, representations, agreements, and understandings are superseded
hereby.  No agreements altering or
supplementing the terms hereof, including the exhibits attached hereto, may be
made except by a written document signed by the duly authorized representatives
of both parties. Any conflicts between the Exhibits and this Agreement are
controlled by this Agreement.

 

9.2                                 This
Agreement shall be construed and enforced in accordance with the laws of the
State of Texas.

 

9.3                                 This
Agreement anticipates educational training and may involve health science
postgraduates and other students of the Institution. Institution shall cause
any such students, and Principal Investigator and Other Investigators who
participate in the Study to perform the Study in accordance with this Agreement
as if they were a party thereto; including without limitation, obligations
commensurate with or that effect the intent of Articles 6 and 7.

 

9.3                                 This
Agreement shall be binding upon the successors and permitted assigns of the
parties; provided, however, that no assignment shall be made by Institution
without the prior written consent of Sponsor. Sponsor may assign this Agreement
without prior written consent of Institution. Any attempt by Institution to
assign this Agreement or any rights or delegate any duties hereunder contrary
to the foregoing provision shall be void and of no legal effect.

 

9.4                                 Any
notices given under this Agreement must be in writing and shall be deemed given
and received five (5) business days after the date of mailing, one (1) calendar
day after dispatch by overnight courier service, by facsimile transmission
(receipt verified) or upon receipt if by hand delivery. Any notices pursuant to
this Agreement shall be sent to the following address:

 

	
  If to Institution:

  	
   

  	
  The University of Texas M.D. Anderson Cancer Center

  
	
   

  	
   

  	
  Address: 1515 Holcombe Blvd., Box 307

  
	
   

  	
   

  	
  Fax: (713) 794-4535

  

 

6

 

	
   

  	
   

  	
  Attention: Melinda Mathis, M.P.A.

  
	
   

  	
   

  	
  Title: Director, Sponsored Programs and Compliance

  
	
   

  	
   

  	
   

  
	
  With a copy to:

  	
   

  	
  The University of Texas M.D. Anderson Cancer Center

  
	
   

  	
   

  	
  Address: 1515 Holcombe Blvd., Box 428

  
	
   

  	
   

  	
  Fax: (713) 792-2031

  
	
   

  	
   

  	
  Attention: Hagop M. Kantarjian, M.D.

  
	
   

  	
   

  	
  Title: Principal Investigator

  
	
   

  	
   

  	
   

  
	
  If to Sponsor:

  	
   

  	
  ChemGenex
  Therapeutics, Inc.

  
	
   

  	
   

  	
  3475 Edison Way,
  Suite M

  
	
   

  	
   

  	
  Menlo Park, CA

  
	
   

  	
   

  	
  Fax: (650) 474-9808

  
	
   

  	
   

  	
  Attention:
  Dennis Brown, Ph.D.

  

 

Each party may change its address for receipt of
notices by giving the other party written notice of the new address.

 

9.5                                 No
right or license is granted under this Agreement by either party to the other,
either expressly or by implication, except those specifically set forth herein.

 

9.6                                 No
failure or delay of one of the parties to insist upon strict performance of any
of its rights or powers under this Agreement shall operate as a waiver thereof,
nor shall any other single or partial exercise of such right or power preclude
any other further exercise of any rights or remedies provided by law.

 

9.7                                 If
any provision of this Agreement should be held invalid or unenforceable, the
remaining provisions shall be unaffected and shall remain in full force and
effect, to the extent consistent with the intent of the parties as evidenced by
this Agreement as a whole.

 

9.8                                 The
relationship between the parties is that of independent contractors, and
neither party shall have the authority to bind or act on behalf of the other
party without obtaining such other party’s prior, written consent.  This Agreement shall not constitute, create,
or in any way be interpreted as a joint venture, partnership or business
organization of any kind.

 

9.9                                 Sections
3.2 and 8.3, and Articles 4, 6, 7 and 9 shall survive any termination of this
Agreement.

 

7

 

IN WITNESS WHEREOF,
Institution and Sponsor hereby enter into this Agreement, effective as of the
date first set forth above, and execute two (2) original counterparts.

 

	
  ChemGenex Therapeutics, Inc.

  	
   

  	
  The University of Texas

  
	
   

  	
   

  	
  M.D. Anderson Cancer Center

  
	
   

  	
   

  	
   

  
	
  BY: 

  	
   

  	
   

  	
   

  	
  BY: 

  	
   

  	
   

  
	
  DATE: 

  	
   

  	
   

  	
   

  	
  DATE: 

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Leonard A. Zwelling, M.D., M.B.A.

  
	
   

  	
   

  	
   

  	
  Vice President for Research Administration

  
										

 

	
  Reviewed & Approved:

  
	
   

  
	
  Date:

  	
   

  

 

	
   

  	
   

  	
  I acknowledge that I have read this Agreement in
  its entirety and that I shall use reasonable efforts to uphold my individual
  obligations and responsibilities set forth herein:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BY: 

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Jorge Cortes-Franco, M.D.

  
	
   

  	
   

  	
   

  	
  Principal Investigator

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BY: 

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Hagop M. Kantjarian, M.D.

  
	
   

  	
   

  	
   

  	
  Chair, Department of Leukemia

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BY:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Waun Ki Hong, M.D.

  
	
   

  	
   

  	
   

  	
  Head, Department of Cancer Medicine

  
						

 

Make Payment To:

The University of Texas

M.D. Anderson Cancer Center

Attn:  Manager, Grants &
Contracts Accounting

P. O. Box 297402

Houston, TX 77297

Tax I.D.  74 6001118 A1

 

8

 

EXHIBIT A

CLINICAL PROTOCOL

 

9

 

EXHIBIT B

 

STUDY BUDGET/PAYMENT SCHEDULE

 

	
  Protocol Administration
  Charges:

  	
   

  	
   

  	
   

  
	
  Institutional Review
  Board

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Pharmacy Set-up

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Miscellaneous, specify:
  PDMS user fee

  	
   

  	
  $

  	
  [*]

  	
   

  

 

 

	
  Patient Study Visit

  	
   

  	
  Cost Per

  Visit/Cycle

  	
   

  	
  Number of

  Visits/Cycles

  	
   

  	
  Maximum Cost Per

  Patient

  	
   

  
	
  Screening + Remission
  Induction 1

  	
   

  	
  $

  	
  [*]

  	
   

  	
  1

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Additional Remission
  Induction

  	
   

  	
  $

  	
  [*]

  	
   

  	
  Up to 2

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Remission Maintenance
  Therapy

  	
   

  	
  $

  	
  [*]

  	
   

  	
  Up to 12

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Study Completion

  	
   

  	
  $

  	
  [*]

  	
   

  	
  1

  	
   

  	
  $

  	
  [*]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Total Max. Cost Per Patient:

  	
   

  	
  $

  	
  [*]

  	
   

  

 

 

Payment Schedule

 

The first installment of [*] is payable within thirty (30) days of the
Effective Date of this Agreement. Subsequent study payments will be made quarterly
in accordance with the number of study visits/treatment cycles completed by
each patient and upon receipt of verifiable, required study data by ChemGenex
Therapeutics, Inc. The final payment will be based upon the total number
of evaluable patients x per visit
cost, less the total of previously issued study payments. An evaluable patient
is defined as an enrolled patient meeting all entry criteria who has completed
induction therapy and all required follow-up per protocol (or who has
terminated early for a study-related reason). The final payment will be issued
upon resolution of all patient data queries.

 

	
  Payment Issue

  	
   

  	
   

  
	
  Payee

  	
   

  	
  The University of Texas, M.D. Anderson 

  
	
   

  	
   

  	
  Cancer Center

  
	
  Address Line 1

  	
   

  	
  Attn: Manager, Grants & Contracts
  Accounting

  
	
  Address Line 2

  	
   

  	
  P.O. Box 297402

  
	
  Address Line 3

  	
   

  	
  Houston, TX 77297

  
	
  Social Security or Federal Tax ID Number

  	
   

  	
  Tax I.D. 74 6001118 A1

  

 

10

 

EXHIBIT C

 

DISCLOSURE OF FINANCIAL INTERESTS AND ARRANGEMENTS

OF PRINCIPAL INVESTIGATOR OR OTHER RESEARCHER

 

As a condition of participating as a clinical investigator in the
protocol entitled, “A Phase II Open-Label Study of the Intravenous
Administration of Homoharringtonine (CGX-635) in the Treatment of
Myelodysplastic Syndrome (MDS)” (the “Study”) which is sponsored by ChemGenex, Inc.
(“ChemGenex”), please provide the appropriate information and responses to the
following statements.

 

Investigator’s Name:  Jorge
Cortes-Franco, M.D.

Title:  Principal Investigator

Organization/Institution:  The
University of Texas M.D. Anderson Cancer Center Date:

 

Please mark the applicable checkboxes.

 

o                                    I
have financial arrangement(s) with ChemGenex in which the value of the
compensation for conducting the Study could be influenced by the outcome of the
Study.

 

o                                    I
have received or will receive from ChemGenex, since February 2, 1999 and
during the time of the Study and for one (1) year after its completion,
payment(s) of other sorts (e.g., grants to fund other ongoing research,
compensation in the form of equipment not for the Study, retainer for ongoing
consultation, or honoraria) that have a monetary value of more than
$25,000.  Such payment(s) exclude the
costs of conducting the Study or other clinical studies.

 

o                                    I
have any proprietary interest(s) in the product or device tested in the Study.

 

o                                    During
the time of the Study and for one (1) year after its completion, I will
hold significant equity interest in ChemGenex. 
“Significant equity interest” means any (1) ownership interest,
stock options or other financial interest whose value cannot be readily
determined through reference to public prices; or (2) equity interest in a
publicly traded corporation that exceeds $50,000.

 

For those statements I have checked, details of the individuals financial
arrangements and interests are attached, along with a description of steps
taken to minimize the potential bias of Study results by any of the disclosed
arrangements or interests.

 

ChemGenex agrees to treat as confidential all financial arrangements
and interests attached to this Exhibit and to use such disclosure to meet
the requirements placed on ChemGenex under 21 CFR 54.  Investigator acknowledges and agrees that
ChemGenex may use such disclosure for this purpose.  During the time of the Study and for one (1) year
after its completion, Investigator shall notify ChemGenex in writing of any
change to the information provided in this Exhibit.

 

	
  Investigator’s signature: 

  	
   

  	
   

  	
   

  	
  Date: 

  	
   

  	
   

  

 

11

 

AMENDMENT No. 1 TO RESEARCH

AGREEMENT

 

This Amendment No. 1 to Research Agreement (“Amendment”) is made
and entered into as of November 18, 2004 by and between ChemGenex
Therapeutics, Inc. (“Sponsor”) and The University of Texas M.D. Anderson
Cancer Center (“Institution”), a component of the University of Texas System (“System”).

 

RECITALS

 

A.                                   Sponsor
and Institution entered into a Sponsored Clinical Study Agreement dated April 14,
2003 (the “Agreement”).

 

B.            Sponsor and
Institution wish to amend the terms of the Agreement as set forth below.

 

NOW, THEREFORE, it is hereby agreed as follows:

 

1.             Section 2 of the
Agreement shall be revised to read in its entirety as follows:

 

2.1                                 In
consideration for performance of the Study by Institution, Sponsor shall pay
Institution a maximum of [*] per patient for Study expenses for up to fifteen
(15) patients, according to the Study budget and payment schedule detailed
in Exhibit B.  This amount, shown by
approximate category of expense in Exhibit B is attached hereto for
information only. The first installment is payable within thirty (30) days of
the Effective Date, and subsequent installments are payable quarterly. In
addition, an amount of [*] previously paid for the APL study will be credited
to the current MDS Study once the MDS contract is executed.  This credit will be applied to the payment schedule described
in Exhibit B.  In no event shall
Sponsor be obligated to pay to Institution any aggregate amount in excess of [*]
($[*]) unless Sponsor consents to do so in writing.  Breach of Section 2.1 shall constitute a
material breach of this Agreement.

 

2.             Exhibit B of the
Agreement shall be revised in its entirety as attached.

 

3.                                       Except
as expressly provided in this Amendment, all other terms, conditions and
provisions of the Agreement shall continue in full force and effect as provided
therein.

 

1

 

EXHIBIT B

 

STUDY BUDGET/PAYMENT SCHEDULE

 

	
  Protocol Administration
  Charges

  	
   

  	
   

  	
   

  
	
  Institutional Review
  Board

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Pharmacy Set-up

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Miscellaneous, specify:
  PDMS user fee

  	
   

  	
  $

  	
  [*]

  	
   

  

 

	
  Patient Study Visit

  	
   

  	
  Cost Per

  Visit/Cycle

  	
   

  	
  Number of

  Visits/Cycles

  	
   

  	
  Maximum Costs Per

  Patient

  	
   

  
	
  Screening+ Remission
  Induction 1

  	
   

  	
  $

  	
  [*]

  	
   

  	
  1

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Additional Remission
  Induction

  	
   

  	
  $

  	
  [*]

  	
   

  	
  Up to 2

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Remission Maintenance

  	
   

  	
  $

  	
  [*]

  	
   

  	
  Up to 12

  	
   

  	
  $

  	
  [*]

  	
   

  
	
  Study Completion

  	
   

  	
  $

  	
  [*]

  	
   

  	
  1

  	
   

  	
  $

  	
  [*]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Total Max. Cost Per Patient:

  	
   

  	
  $

  	
  [*]

  	
   

  

 

Payment Schedule:

 

The first installment of $[*], covering protocol administration
charges, is payable within thirty (30) days of the Effective Date of this
Agreement. Subsequent study payments will be made quarterly in accordance with
the number Study visits/treatment cycles completed by each patient and upon
receipt of verifiable, required Study data by Sponsor.  The final payment will be based upon the total
number of evaluable patients x per visit
cost, less the total of previously issued study payments. In addition, an
amount of [*] previously paid for the APL study will be credited to the current
MDS Study once the MDS contract is executed. 
This credit will be applied according to this payment schedule.  An evaluable patient is defined as an
enrolled patient meeting all entry criteria who has completed the first
treatment cycle and all required follow-up per protocol (or who has terminated
early for a study-related reason).  The
final payment will be issued upon resolution of all patient data queries.

 

	
  Payment Issue

  	
   

  	
   

  
	
  Payee

  	
   

  	
  The University of Texas, 

  
	
   

  	
   

  	
  M.D. Anderson Cancer Center

  
	
  Address Line 1

  	
   

  	
  Attn: Manager, Grants & Contracts
  Accounting

  
	
  Address Line 2

  	
   

  	
  P. O. Box 4390

  
	
  Address Line 3

  	
   

  	
  Houston, TX 77210

  
	
  Social Security or Federal Tax ID Number

  	
   

  	
  Tax I.D. 74 6001118 A1

  

 

2

 

IN WITNESS WHEREOF,
Sponsor and Institution have entered into this Amendment effective as of the
date first set forth above.

 

	
  ChemGenex Therapeutics, Inc.

  	
  THE UNIVERSITY OF TEXAS

  
	
   

  	
   

  
	
  M.D.
  ANDERSON CANCER CENTER

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Leonard A. Zwelling, M.D., M.B.A.

  
	
   

  	
  Vice President for Research Administration

  
	
   

  	
   

  
	
  Date:

  	
   

  	
   

  	
  Date:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  I have read this Amendment and understand my
  obligations hereunder:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Jorge-Cortes Franco, M.D.

  
	
   

  	
   

  	
  Principal Investigator

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Hagop M. Kantarjian, M.D.

  
	
   

  	
   

  	
  Chairman, Department of Leukemia

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Waun Ki Hong, M.D.

  
	
   

  	
   

  	
  Head, Division of Cancer Medicine

  
										

 

	
  Reviewed & Approved:

  
	
   

  
	
  Date:

  	
   

  

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]